

**DISCLAIMER IN PATENT UNDER 37 CFR 1.321(a)**

Name of Patentee Stevens, et al.	Docket Number (Optional) J660-052 US
Patent Number 6,858,633	Date Patent Issued February 22, 2005

Title of Invention SUBSTITUTED 2-ARYLBENZAZOLE COMPOUNDS  
AND THEIR USE AS ANTITUMOUR AGENTS

I hereby disclaim the following complete claims in the above identified patent: \_\_\_\_\_  
1, 2, 3, 4, 5, 7, 9, 32 and 33

The extent of my interest in said patent is (if assignee of record, state liber and page, or reel and frame, where assignment is recorded): 100% by Assignments recorded at Reel/Frame


013389/0075 on 07/29/2002 and 014139/0424 on 06/05/2003

The fee for this disclaimer is set forth in 37 CFR 1.20(d).

- ☐ Patentee claims small entity status. See 37 CFR 1.27.
- ☐ Small entity status has already been established in this case, and is still proper.
- ☐ A check in the amount of the fee is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge any fees which may be required or credit any overpayment to Deposit Account No. 14-1431.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

Signed at LONDON, UK, State of UK, this 26 day of November, 2009.

Signature 		Registration Number, if applicable
CANCER RESEARCH TECHNOLOGY LIMITED		
Name: <u>P. HUILLIER</u>	Title: <u>DIRECTOR, BUSINESS MANAGEMENT</u>	
Typed or printed name of patentee/ attorney or agent of record		Telephone Number
<u>61 LINCOLN'S INN FIELDS</u>		
Address		
<u>LONDON WC2A 3PX, UNITED KINGDOM</u>		
City, State, Zip Code or Foreign Country as applicable		

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.